The Heron Therapeutics Inc. (HRTX) to Post Q1 2017 Earnings of ($0.77) Per Share, Leerink Swann Forecasts

The Heron Therapeutics Inc. (HRTX) to Post Q1 2017 Earnings of ($0.77) Per Share, Leerink Swann Forecasts

Heron Therapeutics Inc. (NASDAQ:HRTX) – Equities research analysts at Leerink Swann issued their Q1 2017 EPS estimates for shares of Heron Therapeutics in a research note issued to investors on Thursday. Leerink Swann analyst J. Gerberry forecasts that the brokerage will earn ($0.77) per share for the quarter. Leerink Swann currently has a “Buy” rating and a $33.00 target price on the stock. Leerink Swann also issued estimates for Heron Therapeutics’ Q2 2017 earnings at ($0.79) EPS, Q3 2017 earnings at ($0.60) EPS and Q4 2017 earnings at ($0.15) EPS.

HRTX has been the subject of several other research reports. Brean Capital initiated coverage on Heron Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $41.00 target price for the company. Lake Street Capital reiterated a “buy” rating and issued a $45.00 price objective on shares of Heron Therapeutics in a research report on Tuesday, September 6th. JMP Securities reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Friday, September 9th. Jefferies Group lowered their price objective on Heron Therapeutics from $46.00 to $40.00 and set a “buy” rating for the company in a research report on Monday. Finally, Zacks Investment Research downgraded Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company’s stock. Heron Therapeutics presently has an average rating of “Buy” and an average target price of $42.14.

Heron Therapeutics (NASDAQ:HRTX) traded down 2.58% during mid-day trading on Friday, reaching $16.59. 245,642 shares of the company traded hands. The company’s 50-day moving average is $18.73 and its 200-day moving average is $18.90. Heron Therapeutics has a 12-month low of $15.13 and a 12-month high of $31.32.

10/07/heron-therapeutics-inc-hrtx-to-post-q1-2017-earnings-of-0-77-per-share-leerink-swann-forecasts.html

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.21.

In related news, insider Robert Rosen sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the completion of the transaction, the insider now owns 102,640 shares in the company, valued at $2,391,512. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 20.31% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. BlackRock Group LTD boosted its stake in Heron Therapeutics by 9.0% in the second quarter. BlackRock Group LTD now owns 10,816 shares of the biotechnology company’s stock worth $195,000 after buying an additional 897 shares in the last quarter. Parametric Portfolio Associates LLC bought a new stake in Heron Therapeutics during the second quarter worth approximately $213,000. BlackRock Advisors LLC boosted its stake in Heron Therapeutics by 13.3% in the second quarter. BlackRock Advisors LLC now owns 15,104 shares of the biotechnology company’s stock worth $273,000 after buying an additional 1,769 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in Heron Therapeutics by 8.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 16,739 shares of the biotechnology company’s stock worth $302,000 after buying an additional 1,283 shares in the last quarter. Finally, American International Group Inc. boosted its stake in Heron Therapeutics by 8.1% in the second quarter. American International Group Inc. now owns 18,293 shares of the biotechnology company’s stock worth $330,000 after buying an additional 1,369 shares in the last quarter.

Heron Therapeutics Company Profile

Related posts

Leave a Comment